Minimal Residual Disease Global Market Report 2025

Description

Minimal residual disease (MRD) refers to the small number of cancer cells that remain in the body after treatment, even when the patient is in clinical remission. Monitoring MRD helps in the early detection of relapse, evaluation of treatment effectiveness, and prediction of recurrence risk. This highly sensitive detection method enables personalized therapies, improving patient outcomes and reducing the chances of relapse.

The primary detection targets for MRD include lymphoma, leukemia, solid tumors, and others. Lymphoma is a type of cancer that originates in the lymphatic system and primarily affects white blood cells called lymphocytes. Various test techniques used for MRD detection include flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others. These tests are utilized by multiple end-users, including hospitals, diagnostic laboratories, research institutions, and industries such as banking, financial services, and insurance (BFSI), as well as retail and e-commerce.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The minimal residual disease market research report is one of a series of new reports from The Business Research Company that provides minimal residual disease market statistics, including the minimal residual disease industry global market size, regional shares, competitors with the minimal residual disease market share, detailed minimal residual disease market segments, market trends, and opportunities, and any further data you may need to thrive in the minimal residual disease industry. This minimal residual disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The minimal residual disease market size has grown rapidly in recent years. It will grow from $1.78 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to increasing number of cancer patients, growing research and development spending, rising healthcare affordability, rising prevalence of blood cancer, and increasing awareness among people.

The minimal residual disease market size is expected to see rapid growth in the next few years. It will grow to $3.19 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to rise in the number of patients with cancer, rise in the government awareness programs, rise in the healthcare affordability, increasing disposable income in emerging economies, and government body initiatives to create awareness about cancer. Major trends in the forecast period include advancements in next-generation sequencing (NGS) technology, standardization of MRD testing, adoption of personalized MRD monitoring, development in liquid biopsy technologies, minimal residual disease-directed therapies.

The forecast of 12.3% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. cancer monitoring by inflating prices of next-generation sequencing panels and digital Polymerase Chain Reaction(PCR) systems developed in Switzerland and South Korea, resulting in delayed relapse detection and higher oncology testing costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of cancer is anticipated to drive the expansion of the minimal residual disease (MRD) market in the coming years. Cancer encompasses a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. Several factors contribute to the increasing prevalence of cancer, including an aging population, greater exposure to environmental carcinogens, unhealthy lifestyles, and genetic predispositions. The rising number of cancer cases has led to a growing demand for precise MRD testing to detect residual cancer cells, enabling early intervention and personalized treatment. This, in turn, enhances relapse prediction and improves patient outcomes. For example, in May 2024, the National Cancer Institute (NCI), a US-based government agency, reported that nearly 20 million new cancer cases and 9.7 million cancer-related deaths occurred worldwide in 2022. Projections for 2040 estimate 29.9 million new cases and 15.3 million cancer-related deaths. As a result, the increasing cancer prevalence is fueling the growth of the MRD market.

Leading companies in the MRD market are prioritizing the development of advanced in vitro diagnostic (IVD) test services to offer personalized therapy options and improve patient outcomes. IVD test services are laboratory-based diagnostic methods designed to detect residual cancer cells following treatment, aiding in relapse prediction and therapy optimization. For instance, in December 2022, Adaptive Biotechnologies Corporation, a US-based biotechnology company, introduced the clonoSEQ Assay for detecting MRD in patients with diffuse large B-cell lymphoma (DLBCL). This test analyzes circulating tumor DNA (ctDNA) in blood samples, providing a highly sensitive, non-invasive method for monitoring cancer progression and identifying early signs of relapse. By offering clinicians a more precise assessment of a patient's disease burden, the assay helps guide tailored treatment plans. Notably, it is the first MRD test for DLBCL to receive Medicare coverage, ensuring broad accessibility across all treatment regimens and time points.

In February 2024, Veracyte, Inc., a US-based cancer diagnostics company, acquired C2i Genomics, Inc. for $70 million. This acquisition incorporates C2i Genomics' whole-genome MRD expertise into Veracyte's diagnostic platform, enhancing its ability to support patients at various stages of cancer care. C2i Genomics, Inc. is a US-based cancer intelligence company specializing in minimal residual disease (MRD) testing.

Major players in the minimal residual disease market are Thermo Fisher Scientific Inc., Amgen Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Kite Pharma Inc., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Grail LLC, Tempus AI Inc., Veracyte Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc.

North America was the largest region in the minimal residual disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in minimal residual disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the minimal residual disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The minimal residual disease market consists of revenues earned by entities by providing services such as cancer monitoring, relapse prediction, personalized treatment plans, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The minimal residual disease market also includes sales of clonality testing kits, MRD detection reagents, and MRD detection panels. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Minimal Residual Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on minimal residual disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for minimal residual disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The minimal residual disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Detection Target: Lymphoma; Leukemia; Solid Tumors; Other Detection Targets
2) By Test Technique: Flow Cytometry; Polymerase Chain Reaction (PCR); Next Generation Sequencing (NGS); Other Test Techniques
3) By End-User: Banking, Financial Services, And Insurance (BFSI); Retail And E-Commerce; Hospitals; Diagnostic Laboratories; Research Institutions
Subsegments:
1) By Lymphoma: Hodgkin Lymphoma; Non-Hodgkin Lymphoma
2) By Leukemia: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia
3) By Solid Tumors: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer
4) By Other Detection Targets: Multiple Myeloma; Neuroblastoma; Sarcomas
Companies Mentioned: Thermo Fisher Scientific Inc.; Amgen Inc.; Laboratory Corporation of America Holdings (LabCorp); Quest Diagnostics Incorporated; Agilent Technologies Inc.; Sysmex Corporation; Bio-Rad Laboratories Inc.; Qiagen N.V.; Exact Sciences Corporation; Kite Pharma Inc.; Natera Inc.; Foundation Medicine Inc.; NeoGenomics Inc.; Guardant Health Inc.; Grail LLC; Tempus AI Inc.; Veracyte Inc.; Adaptive Biotechnologies Corporation; Invivoscribe Inc.; Mission Bio Inc.; ArcherDx Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r34090u

1. Executive Summary

2. Minimal Residual Disease Market Characteristics

3. Minimal Residual Disease Market Trends And Strategies

4. Minimal Residual Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Minimal Residual Disease Growth Analysis And Strategic Analysis Framework

5.1. Global Minimal Residual Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Minimal Residual Disease Market Growth Rate Analysis
5.4. Global Minimal Residual Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Minimal Residual Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Minimal Residual Disease Total Addressable Market (TAM)

6. Minimal Residual Disease Market Segmentation

6.1. Global Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lymphoma
Leukemia
Solid Tumors
Other Detection Targets
6.2. Global Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next Generation Sequencing (NGS)
Other Test Techniques
6.3. Global Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Banking, Financial Services, And Insurance (BFSI)
Retail And E-Commerce
Hospitals
Diagnostic Laboratories
Research Institutions
6.4. Global Minimal Residual Disease Market, Sub-Segmentation Of Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
6.5. Global Minimal Residual Disease Market, Sub-Segmentation Of Leukemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
6.6. Global Minimal Residual Disease Market, Sub-Segmentation Of Solid Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
6.7. Global Minimal Residual Disease Market, Sub-Segmentation Of Other Detection Targets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Multiple Myeloma
Neuroblastoma
Sarcom

7. Minimal Residual Disease Market Regional And Country Analysis

7.1. Global Minimal Residual Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Minimal Residual Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Minimal Residual Disease Market

8.1. Asia-Pacific Minimal Residual Disease Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Minimal Residual Disease Market

9.1. China Minimal Residual Disease Market Overview
9.2. China Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Minimal Residual Disease Market

10.1. India Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Minimal Residual Disease Market

11.1. Japan Minimal Residual Disease Market Overview
11.2. Japan Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Minimal Residual Disease Market

12.1. Australia Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Minimal Residual Disease Market

13.1. Indonesia Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Minimal Residual Disease Market

14.1. South Korea Minimal Residual Disease Market Overview
14.2. South Korea Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Minimal Residual Disease Market

15.1. Western Europe Minimal Residual Disease Market Overview
15.2. Western Europe Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Minimal Residual Disease Market

16.1. UK Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Minimal Residual Disease Market

17.1. Germany Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Minimal Residual Disease Market

18.1. France Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Minimal Residual Disease Market

19.1. Italy Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Minimal Residual Disease Market

20.1. Spain Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Minimal Residual Disease Market

21.1. Eastern Europe Minimal Residual Disease Market Overview
21.2. Eastern Europe Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Minimal Residual Disease Market

22.1. Russia Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Minimal Residual Disease Market

23.1. North America Minimal Residual Disease Market Overview
23.2. North America Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Minimal Residual Disease Market

24.1. USA Minimal Residual Disease Market Overview
24.2. USA Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Minimal Residual Disease Market

25.1. Canada Minimal Residual Disease Market Overview
25.2. Canada Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Minimal Residual Disease Market

26.1. South America Minimal Residual Disease Market Overview
26.2. South America Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Minimal Residual Disease Market

27.1. Brazil Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Minimal Residual Disease Market

28.1. Middle East Minimal Residual Disease Market Overview
28.2. Middle East Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Minimal Residual Disease Market

29.1. Africa Minimal Residual Disease Market Overview
29.2. Africa Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Minimal Residual Disease Market Competitive Landscape And Company Profiles

30.1. Minimal Residual Disease Market Competitive Landscape
30.2. Minimal Residual Disease Market Company Profiles
- 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Laboratory Corporation of America Holdings (LabCorp) Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Minimal Residual Disease Market Other Major And Innovative Companies

31.1. Sysmex Corporation
31.2. Bio-Rad Laboratories Inc.
31.3. Qiagen N.V.
31.4. Exact Sciences Corporation
31.5. Kite Pharma Inc.
31.6. Natera Inc.
31.7. Foundation Medicine Inc.
31.8. NeoGenomics Inc.
31.9. Guardant Health Inc.
31.10. Grail LLC
31.11. Tempus AI Inc.
31.12. Veracyte Inc.
31.13. Adaptive Biotechnologies Corporation
31.14. Invivoscribe Inc.
31.15. Mission Bio Inc.

32. Global Minimal Residual Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Minimal Residual Disease Market

34. Recent Developments In The Minimal Residual Disease Market

35. Minimal Residual Disease Market High Potential Countries, Segments and Strategies

35.1 Minimal Residual Disease Market In 2029 - Countries Offering Most New Opportunities
35.2 Minimal Residual Disease Market In 2029 - Segments Offering Most New Opportunities
35.3 Minimal Residual Disease Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer